Navigation Links
Melatonin may lower prostate cancer risk
Date:1/19/2014

SAN DIEGO Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may suggest decreased risk for developing advanced prostate cancer, according to results presented here at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21.

Melatonin is a hormone that is produced exclusively at night in the dark and is an important output of the circadian rhythm, or the body's inherent 24-hour clock. Many biological processes are regulated by the circadian rhythm, including the sleep-wake cycle. Melatonin may play a role in regulating a range of other hormones that influence certain cancers, including breast and prostate cancers.

"Sleep loss and other factors can influence the amount of melatonin secretion or block it altogether, and health problems associated with low melatonin, disrupted sleep, and/or disruption of the circadian rhythm are broad, including a potential risk factor for cancer," said Sarah C. Markt, M.P.H., doctoral candidate in the Department of Epidemiology at Harvard School of Public Health in Boston. "We found that men who had higher levels of melatonin had a 75 percent reduced risk for developing advanced prostate cancer compared with men who had lower levels of melatonin.

"Our results require replication, but support the public health implication of the importance of maintaining a stable light-dark and sleep-wake cycle," added Markt. "Because melatonin levels are potentially modifiable, further studies of melatonin and prostate cancer risk and progression are warranted."

To investigate the association between urine levels of the main breakdown product of melatonin, 6-sulfatoxymelatonin, and risk of prostate cancer, Markt and colleagues conducted a case-cohort study of 928 Icelandic men from the AGES-Reykjavik cohort between 2002 and 2009. They collected first morning void urine samples at recruitment, and asked the participants to answer a questionnaire about sleep patterns.

The researchers found that one in seven men reported problems falling asleep, one in five men reported problems staying asleep, and almost one in three reported taking sleeping medications.

The median value of 6-sulfatoxymelatonin in the study participants was 17.14 nanograms per milliliter of urine. Men who reported taking medications for sleep, problems falling asleep, and problems staying asleep had significantly lower 6-sulfatoxymelatonin levels compared with men without sleep problems, according to Markt.

Of the study participants, 111 men were diagnosed with prostate cancer, including 24 with advanced disease. The researchers found that men whose 6-sulfatoxymelatonin levels were higher than the median value had a 75 percent decreased risk for advanced prostate cancer. A 31 percent decreased risk for prostate cancer overall was observed as well, but this finding was not statistically significant.

"Further prospective studies to investigate the interplay between sleep duration, sleep disturbance, and melatonin levels on risk for prostate cancer are needed," said Markt.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Study Suggests Link Between Hormone Melatonin and Type 2 Diabetes
2. Spread of Cancer May be Reduced by Maximizing Melatonin by Blocking Blue Light Says Photonic Developments LLC
3. Lipitor Lawsuit News: Pfizer, Inc. Named in Whistleblower Lawsuit Alleging Improper Marketing of Lipitor, Bernstein Liebhard LLP Reports
4. Lower fat content and exercise for the diet of adolescents
5. Black Magic’s Advanced Engineering With Golf Equipment for the Short Game Offers a Top of the Line Gap Wedge That Can Have You Shooting Lower Scores in No Time
6. RF Safe New Year’s Resolutions – Lower Potential Health Risk From Cell Phone Radiation Exposure
7. “10 Sciatica Exercises,” a New Article on Vkool.Com, Gives People Lower Back Stretches for Sciatica Relief -V-Kool
8. Zamansky LLC Comments On the Settlement By Quest Diagnostics And LabCorp. Of America Of The Whistle-Blower Lawsuit
9. UTHealth program results in happier patients, lower costs in esophageal surgery
10. Diet rich in tomatoes may lower breast cancer risk
11. Orriant—a Frontrunner in Corporate Wellness Programs—Boasts Lower Premium Increases for Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... of a new report from the Frank Hawkins Kenan Institute of Private ... business leaders, academics and policy makers identified concrete solutions at the “What’s Next, ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the ... and particularly good news for prostate cancer patients: incidents of cancer is down as ... the report the cancer death rate has dropped from its peak of 215.1 in ...
(Date:1/24/2017)... ... January 24, 2017 , ... American Family Care (AFC) has opened a new ... care for residents in the area. The Bedford clinic will be the nineteenth location ... years by Dave Adams and Dr. Kristina Orio. Adams and Orio also independently own ...
(Date:1/24/2017)... Overland Park, KS (PRWEB) , ... January 24, ... ... rating to Premensa, a leading natural supplement for relieving premenstrual syndrome, or ... premenstrual syndrome at some point. These symptoms can include cramps, constipation, irritability, headaches, ...
(Date:1/24/2017)... ... 2017 , ... “Who Would Have Dreamed: A Novel of Miracles”: a beautiful and poignant ... understand its purpose in her life. “Who Would Have Dreamed: A Novel of Miracles” is ... love of writing. , Sharon shares that she started her spiritual journey later ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Oregon and PUNE, India ... new report published by Allied Market Research, titled, "Cold ... Bakery & Confectionary, Dairy & Frozen Dessert, Meat, Fish ... Global Opportunity Analysis and Industry Forecasts, 2014-2022," projects that ... garner $426,275 million by 2022, growing at a CAGR ...
(Date:1/24/2017)... 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ... 40 finalists in the Regeneron Science Talent Search, the ... for high school seniors. Finalists were selected based on ... projects. The finalists will now go to ... to undergo a rigorous judging process to determine the ...
(Date:1/24/2017)... , Jan 24, 2017 Research and Markets ... Analysis and Trends - Product, Material - Forecast to 2025" ... ... grow at a CAGR of around 5.4% over the next decade ... the prominent trends that the market is witnessing include 3D medical ...
Breaking Medicine Technology: